Skip to Main Content
  • Home
  • Team18
  • Investments27
  • News353
  • Careers2
  • Home
  • Team18
  • Investments27
  • News353
  • Careers2
Back to Investments
Ring 1
Ring 2
Ring 3
Ring 4

AdvanCell

Financing Round

  • Series C
Round Led or Co-led By SymBiosis

AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope.

Related News

  • AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
  • AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need
  • AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies
  • AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth
View Website

Modality

  • Small Molecule

Indication

  • Oncology

Development Status

  • Phase 2
Aardvark Therapeutics
Aeovian Pharmaceuticals
  • Team18
  • Investments27
  • News353
  • Careers2
  • Copyright © 2026 SymBiosis
  • Privacy
  • Disclaimers